Towa Pharmaceutical Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 6 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/05/13 | ¥107.04 | ¥-240.35 | -324.5% |
| 2026/02/12 | ¥73.56 | ¥180.15 | +144.9% |
| 2025/11/10 | ¥62.02 | ¥115.80 | +86.7% |
| 2025/08/06 | ¥63.46 | ¥51.06 | -19.5% |
Shareholder Composition
Updated 2026/08/01Major Holders
Updated 2026/08/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Brown Capital Mgmt Mutual Fd.s-Brown Capital Mgmt Intl Small Company F
|
1.9M | -19.98% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
355.2K | 0.00% | |
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
267.0K | -15.37% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
231.9K | +2.84% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
161.6K | 0.00% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
158.0K | +15.08% |
Dividend History
Updated 2026/08/16| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥40 | -50.0% |
| 2025 | ¥80 | +33.3% |
| 2024 | ¥60 | 0.0% |
| 2023 | ¥60 | -4.8% |
| 2022 | ¥63 | - |
Financial Performance
2026/08/16 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥165,615M | ¥208,859M | ¥227,934M | ¥259,594M |
| Gross Profit | ¥70,185M | ¥72,713M | ¥81,383M | ¥94,729M |
| Operating Income | ¥19,205M | ¥5,514M | ¥17,648M | ¥23,243M |
| Pretax Income | ¥22,476M | ¥5,240M | ¥25,406M | ¥27,957M |
| Net Income | ¥15,914M | ¥2,201M | ¥16,173M | ¥18,986M |
| EPS | ¥316.19 | ¥44.72 | ¥328.59 | ¥385.71 |
| Operating Margin | 11.60% | 2.64% | 7.74% | 8.95% |
| Balance Sheet | ||||
| Total Assets | ¥332,097M | ¥371,347M | ¥430,653M | ¥470,823M |
| Total Equity | ¥132,168M | ¥136,893M | ¥155,892M | ¥171,624M |
| Total Liabilities | ¥199,929M | ¥234,454M | ¥274,761M | ¥299,199M |
| Cash | ¥32,830M | ¥24,257M | ¥29,650M | ¥45,471M |
| Interest-bearing Debt | ¥140,701M | ¥161,518M | ¥203,308M | ¥230,983M |
| Equity Ratio | 39.80% | 36.86% | 36.20% | 36.45% |
| D/E Ratio | 1.06 | 1.18 | 1.30 | 1.35 |
| Cash Flow | ||||
| Operating CF | ¥22,129M | ¥2,544M | ¥8,212M | ¥23,401M |
| Investing CF | -¥59,729M | -¥30,284M | -¥40,394M | -¥31,287M |
| Financing CF | ¥46,540M | ¥17,481M | ¥35,407M | ¥21,567M |
| Free CF | ¥8,553M | -¥27,925M | -¥31,113M | -¥7,822M |
| Efficiency | ||||
| ROE | 12.04% | 1.61% | 10.37% | 11.06% |
| ROA | 4.79% | 0.59% | 3.76% | 4.03% |
Latest IR Information
-
Toa Pharmaceutical Co., Ltd. Q1 2027 Financial Summary (Consolidated) [Japanese GAAP]
For the first quarter of the fiscal year ending March 2027, consolidated net sales were 71,380 million yen, up 9.6% year over year; operating income was 6,519 million yen, up 25.2% YoY; ordinary income was 7,941 million yen (derivative valuation...
Read more -
Regarding the Financial Disclosure Documents
Earnings overview document including trends in net sales and operating income. First quarter results for the fiscal year ending March 2027 and reference materials are posted.
Read more -
Notice of Completion of Payment for Transfer-Restricted Stock as Treasury Stock Acquisition
Disposal of treasury stock completed. Disposed shares: 1,188 common shares; payment per share: 3,835 yen; total payment: 4,555,980 yen. Disposed to three internal directors (excluding outside directors, etc.), payment date: 2026-07-10.
Read more -
Notice of Allotment of Shares in Tanabe Pharma Factory Co., Ltd. (Complete Subsidiary) and Succession of Manufacturing and Marketing Approval
Completely acquired Tanabe Pharma Factory Co., Ltd. as a subsidiary and inherited 17 components and 35 products in its manufacturing and marketing approvals. The acquired shares are 22,602 shares (100%), with transfer planned for late November 2026 and succession of...
Read more -
【Towa Pharmaceutical】Announcement of Executive Changes | June 24, 2026
Towa Pharmaceutical announced the personnel changes at the General Meeting of Shareholders and Board of Directors held on June 24, 2026, revealing new and reappointed directors. President and CEO Ichiro Yoshida will continue in his role, while Koji Nakamura was...
Read more
Latest News (5 items)
-
Average Analyst Rating: strong_buy
Average Target Price: ¥5,267
Rating Score: 1.50 (Based on 6 analysts)
※1=Strong Buy, 5=Strong Sell
Is Towa Pharmaceutical (TSE:4553) Cheap On New Guidance And First Quarter Growth? - simplywall.st ↗
Company Information
About
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. The company operates through two segments; Domestic and Overseas. It provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from tablets, capsules, injectable, patches, eye drops, and other products. The company also offers IT service related to healthcare; disease risk testing services; and sale of quasi drugs. In addition, it is involved in research and development and production of active pharmaceutical ingredients, intermediates, and support business; and planning, development and OEM manufacturing of health foods, pharmaceuticals, general foods, and other miscellaneous merchandizes. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Kadoma, Japan.
